Form 4: Sangamo Therapeutics Director Margaret Horn Receives Significant Equity Grants

Margaret A. Horn, a Director at Sangamo Therapeutics, Inc., was granted 25,000 restricted stock units and 50,000 stock options on June 12, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• Margaret A. Horn, a Director at Sangamo Therapeutics, Inc. (SGMO), acquired 25,000 shares of common stock through a Restricted Stock Unit (RSU) grant on June 12, 2025. These RSUs were granted at a price of $0 and will fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on her continuous service.
• Following this transaction, Ms. Horn beneficially owns 82,650 shares of common stock, which includes 6,251 shares from a December 15, 2022 RSU grant that will vest on December 15, 2025.
• Additionally, Ms. Horn was granted 50,000 stock options on June 12, 2025, with an exercise price of $0.503 per share and an expiration date of June 11, 2035.
• These stock options are immediately exercisable, but any unvested shares purchased are subject to repurchase rights by the Issuer. The options will vest in 12 successive equal monthly installments following the grant date, subject to her continuous service.
• After this transaction, Ms. Horn beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing details routine equity compensation for a director, which aligns their interests with shareholders and is a standard practice. It does not contain negative operational news or significant financial setbacks.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of shareholders, providing an incentive for long-term performance.
• The acquisition of additional equity by a director can be seen as a vote of confidence in the company's future prospects.

Negatives

• The grants are compensation and dilute existing shareholders to some extent, though this is standard practice for director compensation.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's "Continuous Service," meaning if the director leaves the company before vesting dates, unvested awards may be forfeited.
• The value of the stock options and RSUs is dependent on the future performance of Sangamo Therapeutics' stock price.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• The transaction involves a director of the company receiving equity compensation, which is a common type of related party transaction.

Stakeholder Impact

• Shareholders: Potential for slight dilution from new equity grants, but also increased alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned, but the 2018 EIP framework applies to employees as well.
• Management: The director's compensation structure is clarified, providing incentives for continued service and performance.

Next Steps

• The 25,000 RSU grant will vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders.
• The 6,251 shares from the December 15, 2022 RSU grant will vest on December 15, 2025.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the June 12, 2025 grant date.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, SGMO, SEC Form 4, insider transaction, stock options, restricted stock units, RSU grant, director compensation, equity incentive plan, beneficial ownership